Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

5 Dec 2013 07:00

RNS Number : 7365U
Sopheon PLC
05 December 2013
 



FOR IMMEDIATE RELEASE

5 December 2013

 

 

SOPHEON PLC

 

CORPORATE UPDATE

 

 

Sopheon plc ("Sopheon" or "the Group") issues an update on certain corporate matters.

 

Restructuring

 

The Group's capital restructuring was initiated earlier this year following shareholder approval in June, and was made up of two elements; a capital reorganization followed by a capital reduction.

 

The capital reorganization comprised a share consolidation implemented through a two-step process involving a 10,000:1 share consolidation, followed by a 1:500 share subdivision one week later. This procedure reduced the number of shares in issue by a ratio of 20. It also reduced the number of shareholders on the Company's UK share register from approximately 4,000 to just over 200. By the same token shareholders in the Dutch system were expected to fall from over 7,000 to under 2,000. However, as previously noted, we understand that the reduction was not correctly processed by certain brokers in the Netherlands. We believe this means the Dutch shareholder count may have reduced to around 5,000. We have made enquiries and representations in the Netherlands but the board has found the responses unsatisfactory. Accordingly, the board is actively considering the possibility of seeking shareholder approval for a fresh 500:1 consolidation during the first quarter of 2014. We will continue to assess the alternatives, and will update shareholders in due course. 

 

The second element of the restructuring, the capital reduction had the objective of reducing the deficit on the Group's accumulated reserves. This has now been approved by the court, and a certificate has been issued by the Registrar of Companies.

 

Chairman Barry Mence said: "It's good to see the capital reduction concluded, a further milestone in the corporate changes that we started with last year's transfer from Euronext to Alternext. We will continue to assess how to handle the apparent misprocessing of the consolidation procedure by in the Netherlands system, and will revert to shareholders once we have decided our approach"

 

Financing

 

As we have indicated in previous announcements, the Group's facilities with BlueCrest Capital ("BlueCrest") will expire on maturity of the term loan in March 2014. The balances outstanding on the medium-term debt and revolving credit facility are currently $0.36m and $0.40m respectively. The term debt is being paid down monthly and the revolving facility is used to manage short term currency requirements. BlueCrest is winding down its lending business, and therefore these facilities will not be renewed. The board has been exploring replacement facilities and has signed a provisional term sheet in this regard with a major US bank. We will announce further details as and when they become formalized.

 

In addition, the Company has agreed terms with GEM Global Yield Fund Limited ("GEM") to extend the Group's equity line of credit facility for a further two year period up to 23 December 2015. This is the fifth such extension, and the terms of the facility are otherwise unchanged. Sopheon retains full control of the amount and timing of any subscription under the equity line and will be under no obligation to use the facility at any point. Since inception, the facility has been used to raise working capital on one occasion in March 2004, leaving approximately 90% of the original €10m facility available under the extended agreement.

 

CFO Arif Karimjee said: "We have a long standing relationship with GEM, and the equity line is an important component of Sopheon's financing structure. We have no immediate intention of using the facility, however we are delighted to be extending for an additional two years."

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

About GEM

Global Emerging Markets Limited was founded in 1991. GEM is a $3.4b investment group having completed 305 transactions in 65 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. GEM's funds include: CITIC/GEM Fund; VC Bank/GEM Mena Fund*; Kinderhook; GEM Global Yield Fund; GEM India Advisors, BLOM GEM Opportunities Fund and GEM Brazil PE Fund (*GEM exited both its LP and GP stakes in Q1 2010). For more information, please visit www.gemny.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMGZVDVGFZM
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.